Roger Ulrich, Ph.D.

Roger Ulrich received his Ph.D. in cellular and molecular biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He was a senior scientist with both The Upjohn Company and Pharmacia & Upjohn before moving to Abbott Laboratories as a director of drug safety research. He left Abbott to join Merck Research Laboratories – Rosetta Inpharmatics as a senior scientific director. Dr. Ulrich was a co-founder and chief development officer with Calistoga Pharmaceuticals, where he guided the development of CAL-101 (GS1101, idelalisib), an isoform-selective PI3K inhibitor and helped guide the acquisition of Calistoga by Gilead Sciences. As both a member of Acerta Pharma’s founding board of directors and as its chief scientific officer he helped facilitate a majority-share acquisition by AstraZeneca for the development of acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor. He holds several patents, has authored more than 120 publications, and is a fellow of the Academy of Toxicological Science and a senior advisor on the Frazier Life Sciences team.